E-drug: Therapeutics Letter #49: optimal dosing strategy for statins
---------------------------------------------------------------------
I would like to bring to your attention the July/September issue (#49)
of the Therapeutics Letter: "Statin's benefit for secondary prevention
confirmed. What is the optimal dosing strategy?" that has just been
published on the Therapeutics Initiative web-site at
http://www.ti.ubc.ca/pages/letter49.htm
In this Letter (a continuation of Therapeutics Letter #48) we
summarize latest secondary prevention statin trials and discuss 3
different dosing strategies.
Based on the best available evidence we concluded that:
* Statins provide a cardiovascular and total mortality benefit for
patients with clinically evident occlusive vascular disease
(secondary prevention) and a cholesterol of >3.5 mM.
* Large RCTs are required to test different statin dosing strategies
for secondary prevention before making firm recommendations.
I invite you to drop by and have a look at this Letter. Please feel free
to forward this message to any of your friends or colleagues that
might be interested in this topic.
We would appreciate receiving your comments on this Therapeutics
Letter and its possible implications in clinical practice.
Best regards,
Ciprian Jauca
Program Coordinator
Therapeutics Initiative
University of British Columbia
Department of Pharmacology & Therapeutics
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Tel: +1-604-822-0700
Fax: +1-604-822-0701
Email: jauca@ti.ubc.ca
Web: www.ti.ubc.ca
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug